Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811499 · ClinicalTrials.gov registry record · Phase 2
A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00811499 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 25 participants.
The verdict
NCT00811499, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 (versus placebo) in treating ankylosing spondylitis, and to further evaluate the drug's safety. Approximately 130 patients from the US, Canada, Poland and Hungary will be enrolled in this study.
Interventions
- DRUG ARRY-371797, p38 inhibitor; oral
- DRUG Placebo; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-12-16 |
| Est. Completion | 2009-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811499
The ClinicalTrials.gov registry entry for NCT00811499 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ARRY-371797, p38 inhibitor; oral is the first listed.
NCT00811499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811499 about?
NCT00811499 is a clinical study titled "A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis". This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 (versus placebo) in treating ankylosing spondylitis, and to further evaluate the drug's safety. Approximately 130 patients from the US, Canada, Poland and H...
What is the current status of trial NCT00811499?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-12-16. Estimated completion is 2009-09-29.
What interventions are being tested in trial NCT00811499?
The interventions under investigation include: ARRY-371797, p38 inhibitor; oral (DRUG), Placebo; oral (DRUG).
Who is sponsoring clinical trial NCT00811499?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.